AmpliPhi Biosciences CEO to Present at 28th Annual ROTH Conference

Tuesday, March 8, 2016 8:45 am EST



Public Company Information:


SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that M. Scott Salka, AmpliPhi’s CEO, will present a corporate overview on Tuesday, March 15, 2016 at the 28th Annual ROTH Conference at the Ritz Carlton in Dana Point, California.

The presentation is scheduled to begin at 9:00 am Pacific Time. A live webcast of the presentation will be accessible on AmpliPhi’s website at A replay will be available for 30 days following the presentation.

About AmpliPhi Biosciences
AmpliPhi Biosciences Corporation (NYSEMKT:APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. AmpliPhi's product development programs target bacterial infections that are often resistant to existing antibiotic treatments. AmpliPhi is collaborating with a number of leading organizations, including Intrexon Corporation (NYSE: XON), the U.S. Army, The Royal Brompton Hospital in London, UK and UK-based University of Leicester, to advance bacteriophage-based therapies.

For more information, visit

About Bacteriophages
Bacteriophages are naturally occurring viruses that are highly specific for the bacterial hosts they infect. They can rapidly kill their host, amplifying themselves in the process. Bacteriophages are unaffected by antibiotic resistance and are able to disrupt bacterial biofilms. Such biofilms are a major line of defense for bacteria, contributing to antibiotic resistance. Bacteriophages are able to penetrate biofilms and replicate locally to high levels, to produce strong local therapeutic effects.


Company and Investor relations:
AmpliPhi Biosciences
Matt Dansey, +1 858-800-4869
Media relations (USA)
Lazar Partners
Danielle Lewis/Glenn Silver, + 1 212-867-1762
Media Relations (Europe and ROW)
Instinctif Partners
Gemma Howe/Sue Charles, +44 (0)20 7866 7860